ストックスクリーナーアプリを入手
1.23
6.11%
-0.08
プレマーケット:
1.23
前日終値:
$1.31
開ける：
$1.29
24時間の取引高:
183.64K
Relative Volume:
0.88
時価総額：
$46.67M
収益：
$135.87M
当期純損益:
$72.20M
株価収益率:
0.8662
EPS:
1.42
ネットキャッシュフロー:
$45.09M
1週間 パフォーマンス:
-15.17%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
-37.24%
1年 パフォーマンス:
-37.88%
1日の値動き範囲:
$1.22
$1.30
1週間の範囲:
$1.22
$1.48
52週間の値動き範囲:
$0.9006
$3.07
Scynexis Inc Stock (SCYX) Company Profile
SCYX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
1.23 | 46.67M | 135.87M | 72.20M | 45.09M | 1.42 |
|
ZTS
Zoetis Inc
|
165.02 | 74.45B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.49 | 42.91B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.24 | 41.98B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.49 | 24.35B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
11.96 | 14.28B | 15.05B | -883.30M | 1.89B | -0.74 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-22 | 開始されました | Guggenheim | Buy |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-11 | アップグレード | Needham | Hold → Buy |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-10 | 開始されました | ROTH Capital | Buy |
| 2017-05-09 | ダウングレード | Needham | Buy → Hold |
| 2017-03-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-07 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2016-08-17 | 開始されました | Guggenheim | Buy |
| 2016-08-09 | 繰り返されました | Needham | Buy |
| 2016-08-09 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 開始されました | Brean Capital | Buy |
| 2015-12-29 | 開始されました | WBB Securities | Speculative Buy |
| 2015-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-06-10 | 開始されました | Needham | Buy |
| 2014-05-29 | 開始されました | Canaccord Genuity | Buy |
| 2014-05-29 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Scynexis Inc (SCYX) 最新ニュース
FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com
Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail
SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World
Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.
SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com
SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times
SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan
SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada
Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World
SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St
Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com
Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com
SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa
SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com
SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada
Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle
SCYNEXIS announces new $50 million equity sales agreement - Investing.com India
SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan
SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages SCYNEXIS, Inc. In - GuruFocus.com
Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving AverageShould You Sell? - MarketBeat
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Below Two Hundred Day Moving AverageHere's Why - MarketBeat
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc - Yahoo Finance
SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200 Day Moving AverageTime to Sell? - MarketBeat
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - The Manila Times
SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average of $1.82 - MarketBeat
CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha
Potential Price Increase for Synopsys, Inc. (SNPS) After Recent Insider Activity - Knox Daily
Scynexis CEO acquires $27,400 in company stock By Investing.com - Investing.com Canada
Syncona Advances Share Buyback, Bolsters Treasury Shares - TipRanks
Xero buys South African firm for $115m in 'departure' - New Zealand Herald
SCYNEXIS, Inc. (NASDAQ:SCYX) CEO Gonzalez David Angulo Buys 20,000 Shares - MarketBeat
Scynexis CEO acquires $27,400 in company stock - Investing.com
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Better than expected profits forecast for security tech company - The Business Desk
Synopsys Inc. stock rises Friday, still underperforms market - MarketWatch
SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average of $1.83 - MarketBeat
SCYNEXIS Advances Antifungal Treatments, Strengthens Financial Outlook - TipRanks
Scynexis Inc (SCYX) 財務データ
収益
当期純利益
現金流量
EPS
2.12%
0.89%
大文字化:
|
ボリューム (24 時間):